Phaseline

Companies › Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical: clinical trials, targets and expected readouts

7 active drug programs in 12 registered trials: 6 Phase 3, 3 Phase 1, 3 Phase 2; Metabolic and endocrine, Other, Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
setrusumab
Sclerostin inhibitor
SOSTPhase 3Osteogenesis ImperfectaJan 2027
Triheptanoin (UX007, Dojolvi)
Odd-chain triglyceride providing propionyl-CoA for anaplerotic replenishment of TCA cycle
–Phase 3Long-chain Fatty Acid Oxidation Disorders (LC-FAOD); Pyruvate Dehydrogenase Complex DeficiencyAug 2027
DTX301 (avalotcagene ontaparvovec)
AAV8-mediated gene transfer encoding functional OTC
OTCPhase 3OTC DeficiencySep 2027
GTX-102 (apazunersen)
Antisense oligonucleotide targeting UBE3A
UBE3APhase 3Angelman Syndrome–
UX111
Self-complementary adeno-associated virus serotype 9 (scAAV9) carrying the human SGSH gene
SGSHPhase 2MPS IIIAMar 2029
UX016–Phase 1GNE MyopathyDec 2028
UX701 (rivunatpagene miziparvovec)
Nonreplicating recombinant gene transfer vector delivering functional ATP7B gene
ATP7BPhase 1Wilson DiseaseMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06617429GTX-102 (apazunersen)Phase 3Angelman SyndromeOtherJul 2026
NCT06415344GTX-102 (apazunersen)Phase 3Angelman SyndromeOtherOct 2026
NCT07157254GTX-102 (apazunersen)Phase 2Angelman SyndromeOtherOct 2026
NCT06636071setrusumabPhase 3Osteogenesis ImperfectaOtherJan 2027
NCT05768854setrusumabPhase 3Osteogenesis ImperfectaOtherApr 2027
NCT05125809setrusumabPhase 2Osteogenesis ImperfectaOtherApr 2027
NCT05933200Triheptanoin (UX007, Dojolvi)Phase 3Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Metabolic and endocrineAug 2027
NCT05345171DTX301 (avalotcagene ontaparvovec)Phase 3OTC DeficiencyMetabolic and endocrineSep 2027
NCT07511556UX016Phase 1GNE MyopathyNeurologyDec 2028
NCT06340685Triheptanoin (UX007, Dojolvi)Phase 1Pyruvate Dehydrogenase Complex DeficiencyMetabolic and endocrineDec 2028
NCT04884815UX701 (rivunatpagene miziparvovec)Phase 1Wilson DiseaseMetabolic and endocrineMar 2029
NCT02716246UX111Phase 2MPS IIIAMetabolic and endocrineMar 2029

From the company's SEC filings

Cash and short-term investments of $266m on 2026-09-30; operating cash outflow about $452m a year; runway about 7 months at that burn, to May 2027; 3 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Targets

ATP7B (1) OTC (1) SOST (1) SGSH (1) UBE3A (1)

Companies with the same targets

Vivet Therapeutics SAS Orphalan Prime Medicine CAMP4 Therapeutics Arcturus Therapeutics iECURE Amgen GC Biopharma MavriX Bio Ionis Pharmaceuticals

Companies built like this

BioMarin Pharmaceutical Beijing QL Biopharmaceutical Gan & Lee Pharmaceuticals. Biomea Fusion CSPC Ouyi Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.